KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Liabilities (2017 - 2026)

Aquestive Therapeutics has reported Total Liabilities over the past 9 years, most recently at $194.1 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 20.12% year-over-year to $194.1 million; the TTM value through Dec 2025 reached $194.1 million, up 20.12%, while the annual FY2025 figure was $194.1 million, 20.12% up from the prior year.
  • Total Liabilities for Q4 2025 was $194.1 million at Aquestive Therapeutics, up from $167.7 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $194.1 million in Q4 2025 and troughed at $113.7 million in Q1 2021.
  • A 5-year average of $156.5 million and a median of $162.0 million in 2023 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: soared 44.51% in 2021 and later decreased 6.67% in 2023.
  • Year by year, Total Liabilities stood at $144.1 million in 2021, then grew by 21.85% to $175.6 million in 2022, then dropped by 6.67% to $163.9 million in 2023, then decreased by 1.42% to $161.6 million in 2024, then rose by 20.12% to $194.1 million in 2025.
  • Business Quant data shows Total Liabilities for AQST at $194.1 million in Q4 2025, $167.7 million in Q3 2025, and $166.3 million in Q2 2025.